Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy
Year: 2022
Type: editorial
Abstract: Post-translational modifications of proteins in cancer immunity and immunotherapyIn 2018, Tasuku Honjo and James Allison shared the Noble Prize in Physiology and Medicine for their discoveries in cancer immunology and immune checkpoints (ICs).Over the past few decades, with the investigations of ICs, cancer immune therapies have been extensively studied and have progressed all the way to clinical usage for a variety of cancer indications (1).However, limited response (~25% of all cancer types) often due to limited immune response to the tumor, and acquired resistance, markedly restrict clinical application of immune checkpoint inhibitors (ICIs) (1, 2).Therefore, elucidating the mechanisms of tumor immune responses and optimizing combinatorial strategies to promote a more robust immune response to a tumor have gained more attention.Recent studies have pointed to protein post-translational modifications (PTMs) as playing critical roles, either directly or indirectly, in influencing immunotherapeutic efficacy by modulating ICs and/or shaping the tumor immune microenvironments (TIMEs) (3,4).Conceivably, continued focus on these areas of regulation will allow for further development of promising strategies to increase efficacy of cancer immunotherapies (5).Thus, we have assembled this collection of articles to provide an overview as well as original findings for PTMs in cancer immunity and immunotherapy.
Source: Frontiers in Immunology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W4291156287